BetaGlue Technologies spa
BetaGlue Therapeutics is an Italian clinical-stage oncology company developing innovative radiotherapy products for the personalized treatment of solid tumor cancers. Their mission is to bring easy-to-use, cost-effective, and life-changing personalized treatment options to patients worldwide, with a focus on unresectable solid tumors. They are supported by a global Clinical Advisory Board and international advisers, and aim to become a new standard of care in radiotherapy by offering targeted, safe, and effective treatments that improve patient outcomes and accessibility.
Industries
Nr. of Employees
small (1-50)
BetaGlue Technologies spa
Patents
Products
Intratumoral yttrium-90 microsphere radiotherapy platform
A minimally invasive radiotherapeutic system comprising yttrium-90-labelled microspheres delivered in a rapid-polymerizing biocompatible adhesive matrix via percutaneous needle or catheter to treat unresectable solid tumours.
Intratumoral yttrium-90 microsphere radiotherapy platform
A minimally invasive radiotherapeutic system comprising yttrium-90-labelled microspheres delivered in a rapid-polymerizing biocompatible adhesive matrix via percutaneous needle or catheter to treat unresectable solid tumours.
Services
Design and operational delivery of clinical investigations for intratumoural radiotherapeutic devices, including first-in-human and Phase I/II studies.
Execution of advanced in vivo studies using porcine models to evaluate intratumoural deposition, safety, and short-term efficacy of radiotherapeutic matrices.
Establishment and management of long-term supply agreements for surgical adhesive materials and coordination of industrial-scale manufacturing efforts.
Management and coordination of major innovation funding and equity financing to support regulatory milestone achievement and multi-indication clinical development.
Design and operational delivery of clinical investigations for intratumoural radiotherapeutic devices, including first-in-human and Phase I/II studies.
Execution of advanced in vivo studies using porcine models to evaluate intratumoural deposition, safety, and short-term efficacy of radiotherapeutic matrices.
Establishment and management of long-term supply agreements for surgical adhesive materials and coordination of industrial-scale manufacturing efforts.
Management and coordination of major innovation funding and equity financing to support regulatory milestone achievement and multi-indication clinical development.
Expertise Areas
- Interventional radiotherapy and intratumoural delivery
- Clinical trial management and GCP-compliant study execution
- Preclinical translational research and large-animal models
- Radioisotope-based therapeutic development (yttrium-90 microspheres)
Key Technologies
- Yttrium-90 beta-emitting microspheres
- Biocompatible adhesive hydrogel carriers
- Percutaneous needle/catheter delivery systems
- 90Y PET/CT imaging for radioisotope localization
News & Updates
An abstract was published by the American Society of Clinical Oncology (ASCO) describing the use of YntraDose in an advanced large animal model of pancreatic cancer, showing safety and efficacy.
An article in the international peer-reviewed journal ‘In Vivo’ discusses the safety and performance of BAT-90, an innovative radiotherapy platform for unresectable solid liver tumors, showing necrosis and safety in biocompatibility tests.
Securing supply of BioGlue for the manufacture of YntraDose® Oncology Platform.
Enea-Tech Biomedical Foundation invests €6m, bringing the total funding round to €24m.
An abstract was published by the American Society of Clinical Oncology (ASCO) describing the use of YntraDose in an advanced large animal model of pancreatic cancer, showing safety and efficacy.
An article in the international peer-reviewed journal ‘In Vivo’ discusses the safety and performance of BAT-90, an innovative radiotherapy platform for unresectable solid liver tumors, showing necrosis and safety in biocompatibility tests.
Securing supply of BioGlue for the manufacture of YntraDose® Oncology Platform.
Enea-Tech Biomedical Foundation invests €6m, bringing the total funding round to €24m.